Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered Somerville-based biotech avoid bankruptcy.
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...
Carlyle Group's distributable fourth-quarter earnings missed market expectations on Tuesday, eclipsing a strong growth in the ...
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Carlyle Group's distributable earnings for the fourth quarter missed market expectations on Tuesday, overshadowing a strong ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback